A Clinical Trial to Evaluate the Effects of Super Lungs L... | NCT07694284

Studies
A Clinical Trial to Evaluate the Effects of Super Lungs Liquid Drops on Respiratory Comfort, Airway Soothing, and Overall Well-Being

NCT07694284

Sponsor

SuperBonsai Inc.

Status

Active, not recruiting

Last Update Posted

Jul 9, 2026Actual

Enrollment

35Estimated

Phase

Not Applicable

Conditions

Coughing
Throat Irritation

Interventions

Super Lungs Liquid Drops

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jul 2026

Overall Recruitment Status or Expanded Access Status

Active, not recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jul 2, 2026Actual

Primary Completion Date

Aug 2026Estimated

Completion Date

Aug 2026Estimated

First Submitted Date

Jul 2, 2026

First Submission Date that Met QC Criteria

Jul 2, 2026

First Posted Date

Jul 9, 2026Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jul 2, 2026

Last Update Posted Date

Jul 9, 2026Actual

Name	Class
Citruslabs	INDUSTRY

Description Module

Brief Summary

This is a single-group, open-label, fully decentralized (virtual) clinical trial evaluating the effects of Super Lungs Liquid Drops on respiratory comfort, airway soothing, and overall well-being in generally healthy adults aged 18-65 who experience bothersome respiratory symptoms. All 35 enrolled participants will receive the active study product and self-administer 2 mL of the drops daily (two full droppers of 1 mL each, once daily with the first meal of the day) for 12 weeks.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

35Estimated

Label	Type	Description	Intervention Names
Super Lungs Liquid Drops	Experimental		Dietary Supplement: Super Lungs Liquid Drops

Name	Type	Description	Arm Group Labels	Other Names
Super Lungs Liquid Drops	Dietary Supplement	All 35 participants receive Super Lungs Liquid Drops at 2 mL daily (two full droppers of 1 mL each), administered once daily with the first meal of the day, for 12 weeks.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Respiratory comfort	Change in self-reported respiratory comfort assessed by questionnaires.	Baseline, Week 2, Week 4, Week 8, and Week 12
Normal airway function	Change in self-reported normal airway function assessed by questionnaires.	Baseline, Week 2, Week 4, Week 8, and Week 12

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Adults aged 18-65 years.
Over the past two months, has experienced bothersome coughing on a weekly basis.
Anyone who has experienced issues with at least two of the following over the past four weeks: chest tightness or congestion; persistent throat irritation or itchiness; excess mucus or phlegm buildup.
Generally healthy, without any uncontrolled chronic disease.
Willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.
Resides in the United States.
Has access to the internet and a device (smartphone, tablet, or computer) capable of completing online questionnaires.
Willing to follow the study protocol and complete all required assessments.

Exclusion Criteria:

Anyone with a known allergy or sensitivity to any of the study product ingredients.
Anyone with a known allergy to plants in the Asteraceae/Compositae family.
Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.
Anyone currently taking immunosuppressant medications (e.g., cyclosporine, methotrexate, biologics such as adalimumab or infliximab).
Anyone with a diagnosed autoimmune disorder (e.g., lupus, rheumatoid arthritis, multiple sclerosis).
Anyone with uncontrolled hypertension or currently taking antihypertensive medications, diuretics, or corticosteroids.
Anyone currently taking anticoagulant or antiplatelet medications (e.g., warfarin, heparin, clopidogrel).
Anyone with a chronic health condition that could impact their participation in this study, such as cancer, mental health disorders, a history of serious illness in the last three months, a history of substance abuse, or planned surgery during the study period.
Anyone with a history of alcohol use disorder or currently in alcohol recovery.
Anyone currently participating in another research study or who plans to participate in another study during the study period. (

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

65 Years

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

ID	Term
D012120	Respiration Disorders
D012140	Respiratory Tract Diseases
D012818	Signs and Symptoms, Respiratory
D012816	Signs and Symptoms